Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK
Open Access
- 26 January 2010
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 102 (5), 933-939
- https://doi.org/10.1038/sj.bjc.6605528
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 27 references indexed in Scilit:
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional studyBritish Journal of Cancer, 2008
- Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort studyBMJ, 2008
- An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial resultsVaccine, 2008
- Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trialBritish Journal of Cancer, 2008
- Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 VaccinationJNCI Journal of the National Cancer Institute, 2008
- Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trialThe Lancet, 2007
- Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysisThe Lancet Infectious Diseases, 2007
- Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis updateInternational Journal of Cancer, 2007
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006